Intravenous ferric derisomaltose in iron-deficient patients undergoing transcatheter aortic valve implantation due to severe aortic stenosis: study protocol of the randomised controlled IIISAS trial
Introduction Iron deficiency is a prevalent comorbidity in patients with severe aortic stenosis and may be associated with procedural and clinical outcomes after transcatheter aortic valve implantation (TAVI). In the Intravenous Iron Supplement for Iron Deficiency in Patients with Severe Aortic Sten...
Main Authors: | Lars Gullestad, Thor Edvardsen, Anette Borger Kvaslerud, Kaspar Broch, Sara Bardan, Kristoffer Andresen, Sophie Foss Kløve |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2022-09-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/12/9/e059546.full |
Similar Items
-
Outcomes in asymptomatic, severe aortic stenosis.
by: Anette Borger Kvaslerud, et al.
Published: (2021-01-01) -
Advancing Patient Blood Management: Evaluation of Ferric Derisomaltose in a Tertiary Hospital
by: Mohd Muhaimin Kambali, et al.
Published: (2024-05-01) -
Transcatheter Aortic Valve Therapy for Bicuspid Aortic Valve Stenosis
by: Nalin H. Dayawansa, et al.
Published: (2023-10-01) -
Aortic Stenosis Phenotypes and Precision Transcatheter Aortic Valve Implantation
by: Muzamil Khawaja, et al.
Published: (2023-06-01) -
Real-world experience of intravenous ferric derisomaltose evaluated through safety and efficacy reporting in the UK
by: Rhona C. F. Sinclair, et al.
Published: (2022-11-01)